US appeals court supports Lilly in NFkappaB suit with Ariad
This article was originally published in Scrip
Executive Summary
A federal appeals court has overturned a lower court decision and has ruled in favour of Lilly in the case of Ariad Pharmaceuticals et al vs Lilly relating to a US patent that claims to be a broad patent covering methods of treating human disease by regulating NFkappaB cell signalling activity.